INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY), a prominent player in the pharmaceutical industry with a market capitalization of $748 billion, will present the primary overall survival analysis from ...

The U.S. Food and Drug Administration has approved a new treatment for advanced breast cancer. Drugmaker Eli Lilly announced Sept. 25 the approval of Inluriyo, an oral estrogen receptor antagonist, to ...

She put on a bold display with her blunging open neck gown MAYA Jama was a sheer delight in a see-through dress as she attended events as part of London Fashion Week. The Love Island presenter stunned ...

The Pam & Tommy star, 36, showed off her impeccable sense of style in the oversized two-piece, which featured a double-breasted blazer and smart trousers. The English actress stopped for a few ...

Eli Lilly and Co (NYSE:LLY) on Monday shared topline results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) ...

In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy for the next 2 years. On August 27, Eli Lilly and Company announced that its drug, Verzenio (abemaciclib), combined with ...

Eli Lilly has announced that its new therapeutic Verzenio (abemaciclib), given alongside standard endocrine therapy, improves overall survival in people with high-risk, early-stage breast cancer that ...

Eli Lilly and Company announced positive topline results from the primary overall survival (OS) analysis of the phase 3 monarchE trial. Treatment with two years of Verzenio plus endocrine therapy (ET) ...

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...